Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of SAL0140 in uncontrolled hypertension despite treatment with 2 or more drugs
CTR20254681Phase 2Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SAL0140 in hypertension (HTN), resistant hypertension (RH), sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Nov 2025; status: active.
02
Drugs
SAL0140
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on CTR20254681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254681.